Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVO
Alvotech
$9.19
+2.9%
$9.68
$7.35
$13.70
$2.77B0.11144,002 shs202,737 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$174.07
+0.6%
$167.68
$111.09
$183.00
$10.64B0.38499,655 shs157,816 shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$48.34
-0.6%
$44.83
$37.63
$49.30
$10.75B0.681.20 million shs770,537 shs
Viatris Inc. stock logo
VTRS
Viatris
$9.25
-1.0%
$8.77
$6.85
$13.55
$10.86B0.8910.95 million shs6.34 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVO
Alvotech
0.00%+0.55%-13.79%+10.46%-24.17%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+1.07%+0.58%+24.21%+28.17%
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.00%+1.21%+6.29%+19.87%+20.98%
Viatris Inc. stock logo
VTRS
Viatris
0.00%+2.66%+6.20%+21.55%-10.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alvotech stock logo
ALVO
Alvotech
4.0272 of 5 stars
3.54.00.00.03.30.01.9
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.4825 of 5 stars
4.53.00.00.01.91.70.6
QIAGEN N.V. stock logo
QGEN
QIAGEN
3.9229 of 5 stars
1.25.01.74.52.01.71.3
Viatris Inc. stock logo
VTRS
Viatris
2.6584 of 5 stars
1.95.02.50.00.63.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVO
Alvotech
3.00
Buy$18.0095.87% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$220.6726.77% Upside
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.30
Hold$49.402.19% Upside
Viatris Inc. stock logo
VTRS
Viatris
1.80
Reduce$10.4012.43% Upside

Current Analyst Ratings Breakdown

Latest ALVO, QGEN, VTRS, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$250.00
6/26/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $53.00
6/24/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$55.00
6/13/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.00
6/9/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$201.00 ➝ $216.00
6/6/2025
Viatris Inc. stock logo
VTRS
Viatris
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$10.00
6/3/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$196.00 ➝ $201.00
5/12/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
5/5/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVO
Alvotech
$491.98M5.63N/AN/A($1.37) per share-6.71
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M27.04N/AN/A($1.88) per share-92.59
QIAGEN N.V. stock logo
QGEN
QIAGEN
$1.98B5.43$3.21 per share15.08$16.05 per share3.01
Viatris Inc. stock logo
VTRS
Viatris
$14.74B0.74$5.05 per share1.83$15.61 per share0.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVO
Alvotech
-$231.86M$0.3724.8445.95N/A16.42%-36.37%12.70%8/21/2025 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$6.28N/A725.29N/A-93.22%N/A-33.29%9/2/2025 (Estimated)
QIAGEN N.V. stock logo
QGEN
QIAGEN
$83.59M$0.40121.2019.652.464.68%14.61%8.80%7/30/2025 (Estimated)
Viatris Inc. stock logo
VTRS
Viatris
-$634.20M-$3.17N/A3.60N/A-26.45%16.20%7.01%8/7/2025 (Estimated)

Latest ALVO, QGEN, VTRS, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.60N/AN/AN/A$523.97 millionN/A
5/8/2025Q1 2025
Viatris Inc. stock logo
VTRS
Viatris
$0.49$0.50+$0.01-$2.55$3.30 billion$3.25 billion
5/7/2025Q1 2025
Alvotech stock logo
ALVO
Alvotech
-$0.17$0.35+$0.52$0.35N/AN/A
5/7/2025Q1 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVO
Alvotech
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%N/A62.50%N/A
Viatris Inc. stock logo
VTRS
Viatris
$0.485.19%N/AN/A N/A

Latest ALVO, QGEN, VTRS, and ASND Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%7/2/20257/3/20257/10/2025
5/5/2025
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.125.55%5/23/20255/23/20256/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alvotech stock logo
ALVO
Alvotech
N/A
1.73
1.19
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.04
0.71
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.40
3.37
2.83
Viatris Inc. stock logo
VTRS
Viatris
1.02
1.68
0.97

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVO
Alvotech
N/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
70.00%
Viatris Inc. stock logo
VTRS
Viatris
79.88%

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVO
Alvotech
N/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
QIAGEN N.V. stock logo
QGEN
QIAGEN
9.00%
Viatris Inc. stock logo
VTRS
Viatris
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVO
Alvotech
1,032301.48 millionN/ANot Optionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.13 million36.68 millionOptionable
QIAGEN N.V. stock logo
QGEN
QIAGEN
5,765222.29 million202.29 millionOptionable
Viatris Inc. stock logo
VTRS
Viatris
32,0001.17 billion1.17 billionOptionable

Recent News About These Companies

Viatris: The Problem With The Business Model

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVO

$9.19 +0.26 (+2.91%)
Closing price 07/3/2025 02:25 PM Eastern
Extended Trading
$9.22 +0.03 (+0.33%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$174.07 +0.97 (+0.56%)
Closing price 07/3/2025 02:42 PM Eastern
Extended Trading
$174.07 0.00 (0.00%)
As of 08:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

QIAGEN stock logo

QIAGEN NYSE:QGEN

$48.34 -0.30 (-0.62%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$48.00 -0.34 (-0.70%)
As of 08:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Viatris stock logo

Viatris NASDAQ:VTRS

$9.25 -0.09 (-0.96%)
Closing price 07/3/2025 03:49 PM Eastern
Extended Trading
$9.28 +0.03 (+0.34%)
As of 08:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.